Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: A randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated

Annals of Oncology

Volumn 13, Issue 1, 2002, Pages 108-115

  Chen, Y M ^a,b,c   Perng, R P ^a   Lee, Y C ^a   Shih, J F ^a   Lee, C S ^a   Tsai, C M ^a   Whang Peng, J ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Carboplatin; Gemcitabine; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; METOCLOPRAMIDE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; TIME FACTORS;

EID: 0036225431     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf009     Document Type: Article

References (37)

1. Global cancer statistics
2. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data in individual patients from 52 randomized trials
4. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results
5. Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma: A meta-analysis of response, toxicity, and survival
6. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
7. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis
8. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined of an Eastern Cooperative Oncology Group trial
9. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
10. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
11. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
12. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
13. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
14. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
15. Paclitaxel-based therapy in non-small-cell lung cancer: Improved third generation chemotherapy
16. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
17. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
18. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
19. Hypothesis testing: Two-sample inference
20. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer
21. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
22. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
23. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
24. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
25. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer
26. Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: A phase II multicentre trial
27. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
28. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
29. Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer
30. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses
31. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non-small cell lung carcinoma a phase II trial
32. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer
33. Gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: A phase II study
34. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
35. Paclitaxel and carboplatin in metastatic non-small cell lung cancer: Preliminary results of a phase I study
36. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC): A preliminary analysis